Wall Street analysts expect that Sage Therapeutics, Inc. (NASDAQ:SAGE) will announce earnings of ($1.67) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sage Therapeutics’ earnings. The highest EPS estimate is ($1.50) and the lowest is ($2.00). Sage Therapeutics reported earnings of ($1.08) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 54.6%. The company is scheduled to issue its next earnings results after the market closes on Tuesday, August 8th.
On average, analysts expect that Sage Therapeutics will report full year earnings of ($6.75) per share for the current fiscal year, with EPS estimates ranging from ($8.32) to ($5.90). For the next financial year, analysts expect that the firm will report earnings of ($6.20) per share, with EPS estimates ranging from ($8.28) to ($4.26). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Sage Therapeutics.
Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.61) by $0.09.
SAGE has been the subject of several research analyst reports. Needham & Company LLC initiated coverage on shares of Sage Therapeutics in a research report on Monday, May 15th. They issued a “buy” rating and a $82.00 price target for the company. Bank of America Corporation started coverage on shares of Sage Therapeutics in a research note on Friday, May 12th. They set a “buy” rating and a $85.00 price target on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $110.00 target price on shares of Sage Therapeutics in a research note on Wednesday, May 10th. J P Morgan Chase & Co reiterated a “buy” rating and issued a $83.00 target price on shares of Sage Therapeutics in a research note on Monday, April 3rd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $90.00 target price on shares of Sage Therapeutics in a research note on Friday, July 14th. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. Sage Therapeutics has a consensus rating of “Buy” and an average price target of $85.82.
Hedge funds have recently bought and sold shares of the company. Dubuque Bank & Trust Co. bought a new stake in Sage Therapeutics during the second quarter valued at about $167,000. Ameritas Investment Partners Inc. bought a new stake in Sage Therapeutics during the first quarter valued at about $180,000. Dynamic Technology Lab Private Ltd bought a new stake in Sage Therapeutics during the first quarter valued at about $202,000. BlueCrest Capital Management Ltd bought a new stake in Sage Therapeutics during the first quarter valued at about $205,000. Finally, Jane Street Group LLC bought a new stake in Sage Therapeutics during the first quarter valued at about $208,000.
Shares of Sage Therapeutics (NASDAQ:SAGE) traded up 2.70% on Wednesday, reaching $83.61. The company’s stock had a trading volume of 429,398 shares. Sage Therapeutics has a 1-year low of $35.02 and a 1-year high of $88.93. The stock has a 50-day moving average of $78.63 and a 200 day moving average of $66.94. The stock’s market capitalization is $3.12 billion.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Get a free copy of the Zacks research report on Sage Therapeutics (SAGE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
